Health on MSN3d
What To Know About Chronic RhinosinusitisMedically reviewed by Jurairat J. Molina, MD Chronic rhinosinusitis is inflammation of the sinuses and nasal passages that ...
The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...
Clinical Trials Arena on MSN5d
GSK reports positive outcomes from two Phase III trials of treatment for CRSwNPSecondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.
The prevalence of chronic sinusitis in China is about 8 percent, meaning it affects approximately 107 million people, ...
The U.S. Food and Drug Administration (FDA) has accepted GlaxoSmithKlines (NYSE:GSK) biologics license application for ...
With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its ...
FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements ...
In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...
Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...
The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the ...
Full results from the positive Phase III WAYPOINT trial showed AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) significantly reduced nasal polyp severity, the need for subsequent surgery, and ...
London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback